Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer

Journal of Korean Medical Science

Volumn 24, Issue 5, 2009, Pages 945-950

  Kang, Heeseok ^a   Kim, Tae Joong ^a   Choi, Chel Hun ^a   Lee, Jeong Won ^a   Lee, Je Ho ^a   Bae, Duk Soo ^a   Kim, Byoung Gie ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Etoposide; Ifosfamide; Ovarian neoplasms; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; OVARY TUMOR; PHASE 2 CLINICAL TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ETOPOSIDE; FEMALE; HUMANS; IFOSFAMIDE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 75349097129     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.5.945     Document Type: Article

References (30)

1. McMeekin DS, Tillmanns T, Chaudry T, Gold M, Johnson G, Walker J, Mannel R. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol 2004; 95: 157-64.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
3. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000; 18: 106-15.
4. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-93.
5. Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 1998; 16: 3345-52.
6. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R, Favalli G, Kreinberg R, Van Belle S, Hudson I, Verweij J, Ten Bokkel Huinink WW. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61.
7. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996; 63: 89-93.
8. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994; 86: 1530-3.
9. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
10. Bajetta E, Di Leo A, Biganzoli L, Mariani L, Cappuzzo F, Di Bartolomeo M, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14: 2546-51.
11. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinumresistant epithelial ovarian cancer. J Clin Oncol 1994; 12: 60-3.
12. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-10.
13. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1672-6.
14. Maskens AP, Armand JP, Lacave AJ, De Jager RL, Hansen HH, Wolff JP. Phase II clinical trial of VP-16-213 in ovarian cancer. Cancer Treat Rep 1981; 65: 329-30.
15. Hillcoat BL, Campbell JJ, Pepperell R, Quinn MA, Bishop JF, Day A. Phase II trial of VP-16-213 in advanced ovarian carcinoma. Gynecol Oncol 1985; 22: 162-6.
16. Markman M, Hakes T, Reichman B, Lewis JL Jr, Rubin S, Jones W, Almadrones L, Pizzuto F, Hoskins W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992; 10: 243-8.
17. Lissoni AA, Fei F, Rossi R, Fruscio R, Villa A, Zani G. Ifosfamide in the treatment of malignant epithelial ovarian tumors. Oncology 2003; 65 (Suppl 2): 59-62.
18. Hainsworth JD, Greco FA. Etoposide: twenty years later. Ann Oncol 1995; 6: 325-41.
19. Trope CG, Kisic J, Vergote I. Prognostic factors in platinum-resistant ovarian carcinoma treated with ifosfamide-etoposide. Eur J Gynaecol Oncol 2000; 21: 255-9.
20. Bruzzone M, Campora E, Merlini L, Giudici S, Bottero G, Iskra L, Donadio M, Ferrari I, Ragni N. Ifosfamide and etoposide salvage treatment in advanced ovarian cancer. J Chemother 1991; 3: 332-4.
21. Trope C, Kaern J, Vergote I, Vossli S. A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas. Cancer Chemother Pharmacol 1990; 26 (Suppl): S45-7.
22. Aravantinos G, Dimopoulos MA, Kosmidis P, Bafaloukos D, Papadimitriou C, Kiamouris C, Pavlidis N, Sikiotis K, Papakostas P, Skarlos DV. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. Ann Oncol 2000; 11: 607-12.
23. Shaheen M, Stender MJ, McClean JW, Look KY, Einhorn LH. Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. Am J Clin Oncol 2004; 27: 229-31.
24. Vanhoefer U, Schleucher N, Klaassen U, Seeber S, Harstrick A. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Semin Oncol 2000; 27: 8-13.
25. Ozols RF. Treatment of recurrent ovarian cancer: increasing options-"recurrent" results. J Clin Oncol 1997; 15: 2177-80.
26. NCCN Clinical Practice Guidelines in Oncology. Ovarian Cancer.V.I 2008. Available at http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf [accessed on_]
27. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Trope C. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-106.
28. Rose PG. Gemcitabine reverses platinum resistance in platinumresistant ovarian and peritoneal carcinoma. Int J Gynecol Cancer 2005; 15 (Suppl 1): 18-22.
29. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-93.
30. Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 2004; 95: 506-12.